Clinical Trial Update: A Study to Evaluate the Efficacy and Safety of HCP2102 in Essential Hypertension Patients [Phase 3]

View source ↗

Summary

Phase 3 trial update evaluating the efficacy and safety of HCP2102 in essential hypertension has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hypertension

Drugs mentioned

• HCP2102

Snippet

Sponsor: Hanmi Pharmaceutical Company Limited | Conditions: Hypertension | Phase 3 | Status: COMPLETED